Author Of 1 Presentation
YI02.03 - Identifying distinct cognitive phenotypes in multiple sclerosis
Abstract
Background
Cognitive impairment is one of the most disabling symptoms of multiple sclerosis (MS), affecting about 50% of patients.
Objectives
We sought to define homogeneous cognitive phenotypes in a large cohort of MS patients by using a data-driven approach, and to assess their distinctive clinical and MRI features.
Methods
A cohort of 1212 MS patients and 196 healthy controls (HC) from 8 Italian MS centers underwent cognitive evaluation with Rao’s Brief Repeatable Battery and Stroop Color Word Test. A subgroup (172 MS patients and 50 HC) also underwent a 3T MRI examination, including 3D T1-weighted and dual-echo sequences. Latent-profile analysis was used on cognitive tests’ z-scores for identifying cognitive phenotypes. Linear regression and mixed effects models were used to define the clinical and MRI features of each phenotype.
Results
Five cognitive phenotypes were identified, characterized by “preserved-cognition” (19%), “mild verbal memory/semantic fluency” impairment (30%), “mild-multi-domain” impairment (19%), “severe-attention/executive” impairment with mild impairment of other domains (14%), and “severe-multi-domain” impairment (18%). “Preserved-cognition” patients had shorter disease duration and lower Expanded Disability Status Scale (EDSS) score than all other groups, and mildly impaired phenotypes included patients with shorter disease duration and less likely progressive disease compared to severely impaired groups. However, the “preserved-cognition” group also included patients with progressive disease and high EDSS scores, and severely impaired phenotypes were also represented in early MS stages. Comparing each phenotype to “preserved-cognition” group, distinctive MRI features emerged: “mild verbal memory/semantic fluency” patients had reduced hippocampal volume (p=0.02), “mild-multi-domain” reduced cortical gray matter volume (p=0.04), “severe-attention/executive” higher lesion volume (p=0.04) and severe-multi-domain” extensive brain damage (p<0.01 for lesion, brain, gray matter and thalamic volumes).
Conclusions
We identified five cognitive phenotypes of MS patients, with distinctive MRI substrates. By defining homogenous and clinically meaningful groups, this characterization may be useful for future research on cognitive impairment in MS, and for defining personalized management approaches and rehabilitative strategies in clinical practice.
Presenter Of 1 Presentation
YI02.03 - Identifying distinct cognitive phenotypes in multiple sclerosis
Abstract
Background
Cognitive impairment is one of the most disabling symptoms of multiple sclerosis (MS), affecting about 50% of patients.
Objectives
We sought to define homogeneous cognitive phenotypes in a large cohort of MS patients by using a data-driven approach, and to assess their distinctive clinical and MRI features.
Methods
A cohort of 1212 MS patients and 196 healthy controls (HC) from 8 Italian MS centers underwent cognitive evaluation with Rao’s Brief Repeatable Battery and Stroop Color Word Test. A subgroup (172 MS patients and 50 HC) also underwent a 3T MRI examination, including 3D T1-weighted and dual-echo sequences. Latent-profile analysis was used on cognitive tests’ z-scores for identifying cognitive phenotypes. Linear regression and mixed effects models were used to define the clinical and MRI features of each phenotype.
Results
Five cognitive phenotypes were identified, characterized by “preserved-cognition” (19%), “mild verbal memory/semantic fluency” impairment (30%), “mild-multi-domain” impairment (19%), “severe-attention/executive” impairment with mild impairment of other domains (14%), and “severe-multi-domain” impairment (18%). “Preserved-cognition” patients had shorter disease duration and lower Expanded Disability Status Scale (EDSS) score than all other groups, and mildly impaired phenotypes included patients with shorter disease duration and less likely progressive disease compared to severely impaired groups. However, the “preserved-cognition” group also included patients with progressive disease and high EDSS scores, and severely impaired phenotypes were also represented in early MS stages. Comparing each phenotype to “preserved-cognition” group, distinctive MRI features emerged: “mild verbal memory/semantic fluency” patients had reduced hippocampal volume (p=0.02), “mild-multi-domain” reduced cortical gray matter volume (p=0.04), “severe-attention/executive” higher lesion volume (p=0.04) and severe-multi-domain” extensive brain damage (p<0.01 for lesion, brain, gray matter and thalamic volumes).
Conclusions
We identified five cognitive phenotypes of MS patients, with distinctive MRI substrates. By defining homogenous and clinically meaningful groups, this characterization may be useful for future research on cognitive impairment in MS, and for defining personalized management approaches and rehabilitative strategies in clinical practice.
Author Of 2 Presentations
P0516 - BDNF Val66Met polymorphism effect on hippocampal subfields in multiple sclerosis patients (ID 1688)
Abstract
Background
Brain-derived neurotrophic factor (BDNF) can promote neuronal growth and repair, playing a key role in synaptic plasticity, especially in the hippocampus. The BDNF Val66Met polymorphism was shown to strongly affect BDNF function, but its role in modulating gray matter damage in multiple sclerosis (MS) patients is still not clear.
Objectives
Considering BDNF relevance on hippocampal function, we aimed to explore the effect of BDNF Val66Met polymorphism on the atrophy of hippocampal subfields and its role in cognitive functioning in MS patients.
Methods
Using a 3T scanner, we obtained dual-echo and 3DT1-weighted sequences from 50 MS patients and 15 healthy controls (HC). MS patients also underwent genotype analysis of BDNF and an extensive neuropsychological evaluation. Hippocampal subfields were segmented by using Freesurfer 7.0.1 software. Multiple linear regression models adjusted for age, sex and disease duration were used for between-group comparisons and analysis of associations.
Results
The BDNF Val66Met polymorphism was found in 22 MS patients (44%). Compared to HC, MS patients had reduced volumes of: bilateral hippocampus-amygdala transition area (HATA); left cornus ammonis (CA)1, CA3 and granule cell layer of dentate gyrus (GCL-DG); and right fimbria and presubiculum. BDNF Val66Met polymorphism carriers compared to wild-type (Val66Val) MS patients had higher volume of left hippocampal CA1, CA3, CA4, GCL-DG, molecular layer of subiculum and HATA; and of right hippocampal tail, fissure and presubiculum. In MS patients, higher volume in left CA3 and in right presubiculum correlated with better performance in semantic fluency, while higher volume in left GCL-DG correlated with better visuo-spatial memory performance.
Conclusions
The BNDF Val66Met polymorphism has a protective role in MS patients against both hippocampal atrophy and cognitive deterioration. BDNF genotype may be a potential biomarker for predicting cognitive prognosis, and an interesting target to study for neuroprotective strategies.
P1075 - Early clinical and MRI predictors of long-term disability in pediatric multiple sclerosis patients (ID 1187)
Abstract
Background
The main clinical and MRI features driving therapeutic choices are not as clear for pediatric multiple sclerosis (MS) patients as for adults.
Objectives
We aimed at assessing early predictors of long-term clinically-relevant outcomes in a large cohort of pediatric MS patients.
Methods
Clinical and MRI assessment was obtained at disease onset and after 1, 2 and 3 years, in a cohort of 123 pediatric MS patients. The longest clinical follow-up (mean 9.33 +/- 3.45 years) was considered for long-term outcomes. Cox proportional hazards models were used to assess predictors of time to first relapse, while multivariable logistic and linear regression models identified clinical and MRI predictors of long-term outcomes.
Results
Across baseline features, optic nerve involvement predicted a shorter time to first relapse (hazard ratio=1.9, p=0.03). Predictors of annualized relapse rate (ARR) were: at baseline, presence of cerebellar (b=-0.16, p=0.00) and number of cervical cord lesions (b=0.14, p=0.01); considering short-term predictors, the same baseline variables together with time to first relapse (2-year: b=-0.12, p=0.01; 3-year: b=-0.08, p=0.00) and the number of relapses (1-year: b=0.14, p=0.00; 2-year: b=0.06, p=0.02). Baseline predictors of 10-year disability worsening were: at baseline, presence of optic nerve [odds ratio(OR)=6.45, p=0.01] and brainstem lesions (OR=6.17, p=0.04); considering short-term predictors, Expanded Disability Status Scale (EDSS) changes at 1 (OR=26.05, p=0.00) and 2 (OR= 16.38, p=0.02) years and the detection of at least two new T2-lesions in 2 years (2-year: OR=4.91, p=0.02; 3-year: OR=5.49, p=0.09). Predictors of higher 10-year EDSS score were: at baseline, EDSS score (b=0.58, p<0.001), presence of brainstem (b=0.31, p=0.04) and number of cervical cord lesions (b=0.22, p=0.05); considering short-term predictors, EDSS changes (1-year: b=0.82, p<0.001; 2-year: b=0.79, p<0.001, 3-year: b=0.27, p=0.04 ), together with the detection of at least two new T2-lesions at 1 (b=0.28, p=0.03) and 2 (b=0.35, p=0.01) years.
Conclusions
In conclusion, baseline spinal cord, brainstem and optic nerve lesions have a major role in predicting long-term outcomes, both in term of disease activity and of disability worsening. In addition, an accurate clinical and MRI monitoring during the first 2 years of disease has proven to represent a powerful tool for counseling patients about long-term prognosis and personalizing treatment strategies.
Presenter Of 2 Presentations
P0516 - BDNF Val66Met polymorphism effect on hippocampal subfields in multiple sclerosis patients (ID 1688)
Abstract
Background
Brain-derived neurotrophic factor (BDNF) can promote neuronal growth and repair, playing a key role in synaptic plasticity, especially in the hippocampus. The BDNF Val66Met polymorphism was shown to strongly affect BDNF function, but its role in modulating gray matter damage in multiple sclerosis (MS) patients is still not clear.
Objectives
Considering BDNF relevance on hippocampal function, we aimed to explore the effect of BDNF Val66Met polymorphism on the atrophy of hippocampal subfields and its role in cognitive functioning in MS patients.
Methods
Using a 3T scanner, we obtained dual-echo and 3DT1-weighted sequences from 50 MS patients and 15 healthy controls (HC). MS patients also underwent genotype analysis of BDNF and an extensive neuropsychological evaluation. Hippocampal subfields were segmented by using Freesurfer 7.0.1 software. Multiple linear regression models adjusted for age, sex and disease duration were used for between-group comparisons and analysis of associations.
Results
The BDNF Val66Met polymorphism was found in 22 MS patients (44%). Compared to HC, MS patients had reduced volumes of: bilateral hippocampus-amygdala transition area (HATA); left cornus ammonis (CA)1, CA3 and granule cell layer of dentate gyrus (GCL-DG); and right fimbria and presubiculum. BDNF Val66Met polymorphism carriers compared to wild-type (Val66Val) MS patients had higher volume of left hippocampal CA1, CA3, CA4, GCL-DG, molecular layer of subiculum and HATA; and of right hippocampal tail, fissure and presubiculum. In MS patients, higher volume in left CA3 and in right presubiculum correlated with better performance in semantic fluency, while higher volume in left GCL-DG correlated with better visuo-spatial memory performance.
Conclusions
The BNDF Val66Met polymorphism has a protective role in MS patients against both hippocampal atrophy and cognitive deterioration. BDNF genotype may be a potential biomarker for predicting cognitive prognosis, and an interesting target to study for neuroprotective strategies.
P1075 - Early clinical and MRI predictors of long-term disability in pediatric multiple sclerosis patients (ID 1187)
Abstract
Background
The main clinical and MRI features driving therapeutic choices are not as clear for pediatric multiple sclerosis (MS) patients as for adults.
Objectives
We aimed at assessing early predictors of long-term clinically-relevant outcomes in a large cohort of pediatric MS patients.
Methods
Clinical and MRI assessment was obtained at disease onset and after 1, 2 and 3 years, in a cohort of 123 pediatric MS patients. The longest clinical follow-up (mean 9.33 +/- 3.45 years) was considered for long-term outcomes. Cox proportional hazards models were used to assess predictors of time to first relapse, while multivariable logistic and linear regression models identified clinical and MRI predictors of long-term outcomes.
Results
Across baseline features, optic nerve involvement predicted a shorter time to first relapse (hazard ratio=1.9, p=0.03). Predictors of annualized relapse rate (ARR) were: at baseline, presence of cerebellar (b=-0.16, p=0.00) and number of cervical cord lesions (b=0.14, p=0.01); considering short-term predictors, the same baseline variables together with time to first relapse (2-year: b=-0.12, p=0.01; 3-year: b=-0.08, p=0.00) and the number of relapses (1-year: b=0.14, p=0.00; 2-year: b=0.06, p=0.02). Baseline predictors of 10-year disability worsening were: at baseline, presence of optic nerve [odds ratio(OR)=6.45, p=0.01] and brainstem lesions (OR=6.17, p=0.04); considering short-term predictors, Expanded Disability Status Scale (EDSS) changes at 1 (OR=26.05, p=0.00) and 2 (OR= 16.38, p=0.02) years and the detection of at least two new T2-lesions in 2 years (2-year: OR=4.91, p=0.02; 3-year: OR=5.49, p=0.09). Predictors of higher 10-year EDSS score were: at baseline, EDSS score (b=0.58, p<0.001), presence of brainstem (b=0.31, p=0.04) and number of cervical cord lesions (b=0.22, p=0.05); considering short-term predictors, EDSS changes (1-year: b=0.82, p<0.001; 2-year: b=0.79, p<0.001, 3-year: b=0.27, p=0.04 ), together with the detection of at least two new T2-lesions at 1 (b=0.28, p=0.03) and 2 (b=0.35, p=0.01) years.
Conclusions
In conclusion, baseline spinal cord, brainstem and optic nerve lesions have a major role in predicting long-term outcomes, both in term of disease activity and of disability worsening. In addition, an accurate clinical and MRI monitoring during the first 2 years of disease has proven to represent a powerful tool for counseling patients about long-term prognosis and personalizing treatment strategies.